Balyasny Asset Management
CARM

Balyasny Asset Management’s Carisma Therapeutics CARM Stock Holding History

Balyasny Asset Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,534
Closed -$30K – 2811
2022
Q3 		$30K Buy
3,534
+1,840
+109% +$25.1K ﹤0.01% 2530
2022
Q2 		$27K Buy
+1,694
New +$19.4K ﹤0.01% 2443
2021
Q2 		– Sell
-2,185
Closed -$114K – 1986
2021
Q1 		$114K Buy
+2,185
New +$103K ﹤0.01% 1630

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BWA
Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's CARM Position: Q4 2022 in Review

Balyasny Asset Management sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 3,534 shares — an estimated $30K sold.

Balyasny Asset Management first reported a position in CARM in Q1 2021 and held it in 3 quarters. The position peaked at $114K in Q1 2021. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

  • Balyasny Asset Management reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 3,534 Carisma Therapeutics shares in Q4 2022, an estimated $30K.
  • Balyasny Asset Management first reported a position in Carisma Therapeutics in Q1 2021 and held it in 3 quarters.
  • Balyasny Asset Management's Carisma Therapeutics position peaked at $114K in Q1 2021.
  • 70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.